Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / RIGHT 10/15/2029
-
Total 13F shares
-
18,277,728
-
Share change
-
+4,126,174
-
Total reported value
-
$2,217,081
-
Price per share
-
$0.12
-
Number of holders
-
24
-
Value change
-
+$501,585
-
Number of buys
-
8
-
Number of sells
-
3
Institutional Holders of Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) as of Q2 2025
As of 30 Jun 2025,
Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,277,728 shares.
The largest 10 holders included
TORONTO DOMINION BANK, Polar Asset Management Partners Inc., Hudson Bay Capital Management LP, Harraden Circle Investments, LLC, GLAZER CAPITAL, LLC, ARISTEIA CAPITAL, L.L.C., MANGROVE PARTNERS IM, LLC, Crossingbridge Advisors, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, and CLEAR STREET LLC.
This page lists
24
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.